# Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct03391869/  
OnCo record `nct03391869` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of ipilimumab and nivolumab in lung cancer, run by M.D. Anderson Cancer Center, active but no longer recruiting.

## Summary

Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT03391869 by M.D. Anderson Cancer Center, with a registry enrolment figure of 339 participants, started 2017-12-29 and due to reach its primary completion in 2027-03-31. Interventions recorded: Ipilimumab; Local Consolidation Therapy; Nivolumab; Quality-of-Life Assessment; Radiation Therapy; Therapeutic Conventional Surgery. Conditions listed: Lung Adenocarcinoma; Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8. Primary outcome: Overall survival (OS) in overall population; OS in oligometastatic subgroup. Lung eligibility wording from the registry: "* Histologically or cytologically confirmed non-small cell lung cancer; if a diagnostic biopsy is available, a pre-treatment biopsy is not required". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT03391869
- Phase: 3
- Setting: Randomized Phase III Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab for Immunotherapy-Naive Patients With Metastatic Non-Small Cell Lung Cancer (LONESTAR)
- Sponsor: M.D. Anderson Cancer Center
- Enrolled: 339

## Sources

- ClinicalTrials.gov NCT03391869: https://clinicaltrials.gov/study/NCT03391869

## Connected records

- cancers: [Adenocarcinoma of the lung](https://onco.cc/cancers/lung-adenocarcinoma/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- drugs: [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct03391869.json